CD276 and neoplasm: One of these studies is a TAA06–CART-cell-based clinical trial (clinical trials.gov NCT05190185) using genetically modified T-lymphocytes that express a CAR targeting B7-H3 with immunostimulatory and antitumor activity, ultimately inducing selective toxicity to B7-H3 expressing tumor cells.